Last updated on July 2019

CREST-2 Registry (C2R)


Other Details:

The cohort of subjects for inclusion in this study is symptomatic as a result of their persistent atrial fibrillation and the failure of class I or III antiarrhythmic drug therapy. Phased RF ablation therapy offers the opportunity to reduce the episodes of atrial fibrillation and therefore reduce symptoms. Catheter ablation therapy in subjects with paroxysmal atrial fibrillation have shown improvements in symptoms and reduced episodes of atrial fibrillation.

In the United States there are no approved ablation catheters approved to treat subjects with persistent atrial fibrillation. If successful, the VICTORY AF study could demonstrate meaningful therapeutic benefit in this underserved population. In Europe, Phased RF ablation catheters are approved to treat subjects with persistent atrial fibrillation. If successful, the VICTORY AF study could confirm meaningful therapeutic benefit in this underserved population.



Find a site near you

Start Over

Baptist Health Lexington Clinical Research Center

1740 Nicholasville Road Lexington, KY USA
  Connect »